regulatory challenges

"Biotech in the Balance" - Dr. Jeremy Levin, Chairperson of Ovid Therapeutics

Dr. Jeremy Levin on restoring biotech industry trust through transparency, navigating drug pricing complexity, and competing with China's biotech priorities.

FDA-authorized digital medical devices have grown substantially over two decades, but regulatory databases still can't track them

A Nature study finds digital device authorizations have surged over 20 years, yet FDA databases still can't identify which devices have software inside.

Exploring Artificial Intelligence in Drug Discovery

AI is cutting drug development timelines in half while helping biotech companies identify viable compounds faster and more accurately than traditional methods

2024 Year in Review and 2025 Trends: Insights from the Modular Building Institute

Industry leaders reveal how modular construction tripled its market share in seven years and where growth accelerates next

AI to Enhance Efficiency and Ensure Content Integrity in the Material Review Process in Life Sciences Sector

Automating complex document reviews allows life sciences companies to accelerate timelines while maintaining compliance standards

Amanda Hausmann: What are your thoughts on the Ntracts Advisory Council and what do you get out of it?

Healthcare leaders gain competitive advantages by tapping into peer networks and expert guidance on critical compliance and contract challenges